Anthropic’s $400M Coefficient Bio Bet: What the Drug Discovery Acquisition Really Signals
Anthropic’s Coefficient Bio acquisition — a $400M all-stock deal for fewer than 10 people — is the AI lab’s first major purchase and a direct bet on owning the reasoning layer in pharmaceutical R&D. The team behind Genentech’s AI drug discovery work is now inside Anthropic, building agents for clinical trials, regulatory workflows, and molecule design. Here’s what it means for pharma CTOs, biotech founders, and life-sciences investors before the rest of the market catches up.